Surveillance of antibiotic resistance in invasive isolates of Neisseria meningitidis in Australia 1994-1999. 2001

J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
The Prince of Wales Hospital, Sydney, NSW, Australia.

A total of 1434 strains of Neisseria meningitidis isolated from cases of invasive meningococcal disease (IMD) in Australia between 1994 and 1999 were examined by standard methods for susceptibility to antibiotics used for treatment and prophylaxis. The proportion of isolates fully susceptible to penicillin decreased from 45% in 1994 to 26% in 1999 (P<0.001). All the other isolates were less sensitive to penicillin except for two meningococci with a penicillin MIC of 1 mg/l. The geometric mean penicillin MIC increased from 0.045 to 0.065 mg/l from 1994 to 1999. There was no significant difference in the geometric mean penicillin MICs of serogroup B and serogroup C meningococci. Penicillin susceptibility was significantly associated with a poorer outcome. Isolates from survivors of IMD had a higher geometric mean penicillin MIC (0.06 mg/l) than those from fatal cases (0.048 mg/l) (P< 0.001). This suggests that factors other than the decrease in susceptibility to penicillin observed were more relevant to outcome in IMD. All isolates were fully susceptible to ceftriaxone. Rifampicin resistance was infrequent (eight isolates in 6 years) and sporadic. A single isolate had decreased quinolone susceptibility. Despite the significant shift in susceptibility to penicillin recorded, this group of antibiotics remains a suitable treatment for IMD in Australia.

UI MeSH Term Description Entries
D008589 Meningococcal Infections Infections with bacteria of the species NEISSERIA MENINGITIDIS. Meningococcal Septicemia,Infections, Meningococcal,Meningococcal Disease,Infection, Meningococcal,Meningococcal Diseases,Meningococcal Infection,Septicemia, Meningococcal
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D011159 Population Surveillance Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy. Surveillance, Population
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D001315 Australia The smallest continent and an independent country, comprising six states and two territories. Its capital is Canberra. Canton and Enderbury Islands,Christmas Island,Christmas Island (Australia)

Related Publications

J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
January 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
December 1995, The West Indian medical journal,
J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
November 1991, BMJ (Clinical research ed.),
J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
January 2021, PloS one,
J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
April 2002, Sexually transmitted diseases,
J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
July 2012, Infection and immunity,
J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
October 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
June 2007, Journal of clinical microbiology,
J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
July 2018, Journal of clinical microbiology,
J W Tapsall, and T Shultz, and E Limnios, and R Munro, and J Mercer, and R Porritt, and J Griffith, and G Hogg, and G Lum, and A Lawrence, and D Hansman, and P Collignon, and P Southwell, and K Ott, and M Gardam, and C J Richardson, and J Bates, and D Murphy, and H Smith, and
June 2022, Microbiology spectrum,
Copied contents to your clipboard!